Published in Pharmacol Rev on March 01, 2001
FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat Genet (2010) 5.22
The properties of high-dimensional data spaces: implications for exploring gene and protein expression data. Nat Rev Cancer (2008) 3.43
Loss of nuclear localized and tyrosine phosphorylated Stat5 in breast cancer predicts poor clinical outcome and increased risk of antiestrogen therapy failure. J Clin Oncol (2011) 2.78
Regulation of ERBB2 by oestrogen receptor-PAX2 determines response to tamoxifen. Nature (2008) 2.51
Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients. Br J Cancer (2002) 2.44
Regulation of estrogen receptor alpha by the SET7 lysine methyltransferase. Mol Cell (2008) 2.35
CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer (2009) 2.32
Pathways to tamoxifen resistance. Cancer Lett (2007) 2.12
Total syntheses, fragmentation studies, and antitumor/antiproliferative activities of FR901464 and its low picomolar analogue. J Am Chem Soc (2007) 1.66
Retracted GREB1 functions as a growth promoter and is modulated by IL6/STAT3 in breast cancer. PLoS One (2012) 1.52
Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells. Nat Rev Cancer (2011) 1.51
Endoplasmic reticulum stress, the unfolded protein response, autophagy, and the integrated regulation of breast cancer cell fate. Cancer Res (2012) 1.47
ER-alpha36, a novel variant of ER-alpha, is expressed in ER-positive and -negative human breast carcinomas. Anticancer Res (2008) 1.43
Glucose-regulated protein 78 controls cross-talk between apoptosis and autophagy to determine antiestrogen responsiveness. Cancer Res (2012) 1.41
Deregulation of estrogen receptor coactivator proline-, glutamic acid-, and leucine-rich protein-1/modulator of nongenomic activity of estrogen receptor in human endometrial tumors. J Clin Endocrinol Metab (2004) 1.41
Constitutively nuclear FOXO3a localization predicts poor survival and promotes Akt phosphorylation in breast cancer. PLoS One (2010) 1.40
Functional implications of altered subcellular localization of PELP1 in breast cancer cells. Cancer Res (2005) 1.39
Autophagy and endocrine resistance in breast cancer. Expert Rev Anticancer Ther (2011) 1.29
Oncogenic potential of the nuclear receptor coregulator proline-, glutamic acid-, leucine-rich protein 1/modulator of the nongenomic actions of the estrogen receptor. Cancer Res (2007) 1.28
Minireview: Inflammation: an instigator of more aggressive estrogen receptor (ER) positive breast cancers. Mol Endocrinol (2012) 1.27
Gene network signaling in hormone responsiveness modifies apoptosis and autophagy in breast cancer cells. J Steroid Biochem Mol Biol (2009) 1.26
Co-inhibition of BCL-W and BCL2 restores antiestrogen sensitivity through BECN1 and promotes an autophagy-associated necrosis. PLoS One (2010) 1.22
The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy. Endocr Relat Cancer (2009) 1.19
Ron receptor tyrosine kinase activation confers resistance to tamoxifen in breast cancer cell lines. Neoplasia (2010) 1.15
BCL2 and CASP8 regulation by NF-kappaB differentially affect mitochondrial function and cell fate in antiestrogen-sensitive and -resistant breast cancer cells. FASEB J (2010) 1.14
The immune system and inflammation in breast cancer. Mol Cell Endocrinol (2013) 1.12
Clinical potential of novel therapeutic targets in breast cancer: CDK4/6, Src, JAK/STAT, PARP, HDAC, and PI3K/AKT/mTOR pathways. Pharmgenomics Pers Med (2014) 1.09
The role of ErbB3 and its binding partners in breast cancer progression and resistance to hormone and tyrosine kinase directed therapies. J Mammary Gland Biol Neoplasia (2008) 1.09
IFNgamma restores breast cancer sensitivity to fulvestrant by regulating STAT1, IFN regulatory factor 1, NF-kappaB, BCL2 family members, and signaling to caspase-dependent apoptosis. Mol Cancer Ther (2010) 1.04
Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Res (2012) 1.03
LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer. Oncogene (2015) 1.03
Tamoxifen inhibits malignant peripheral nerve sheath tumor growth in an estrogen receptor-independent manner. Neuro Oncol (2010) 1.02
ACK1/TNK2 tyrosine kinase: molecular signaling and evolving role in cancers. Oncogene (2014) 0.98
Endoplasmic reticulum stress, the unfolded protein response, and gene network modeling in antiestrogen resistant breast cancer. Horm Mol Biol Clin Investig (2011) 0.97
Influence of berry polyphenols on receptor signaling and cell-death pathways: implications for breast cancer prevention. J Agric Food Chem (2012) 0.97
The phosphorylated prodrug FTY720 is a histone deacetylase inhibitor that reactivates ERα expression and enhances hormonal therapy for breast cancer. Oncogenesis (2015) 0.96
Hydroxychloroquine inhibits autophagy to potentiate antiestrogen responsiveness in ER+ breast cancer. Clin Cancer Res (2014) 0.95
ACK1 tyrosine kinase interacts with histone demethylase KDM3A to regulate the mammary tumor oncogene HOXA1. J Biol Chem (2014) 0.93
Endocrine resistance in breast cancer - An overview and update. Mol Cell Endocrinol (2015) 0.93
Orphan nuclear receptors in breast cancer pathogenesis and therapeutic response. Endocr Relat Cancer (2010) 0.93
The effects of tamoxifen on immunity. Curr Med Chem (2009) 0.92
Knockdown of estrogen receptor-α induces autophagy and inhibits antiestrogen-mediated unfolded protein response activation, promoting ROS-induced breast cancer cell death. FASEB J (2014) 0.92
The role of preclinical animal models in breast cancer drug development. Breast Cancer Res (2009) 0.91
Breast cancer oestrogen independence mediated by BCAR1 or BCAR3 genes is transmitted through mechanisms distinct from the oestrogen receptor signalling pathway or the epidermal growth factor receptor signalling pathway. Breast Cancer Res (2004) 0.91
Endoxifen's molecular mechanisms of action are concentration dependent and different than that of other anti-estrogens. PLoS One (2013) 0.91
Mechanism of estradiol-induced block of voltage-gated K+ currents in rat medial preoptic neurons. PLoS One (2011) 0.89
Tamoxifen resistance and epigenetic modifications in breast cancer cell lines. Curr Med Chem (2007) 0.89
Autophagy: friend or foe in breast cancer development, progression, and treatment. Int J Breast Cancer (2011) 0.89
Prolylcarboxypeptidase regulates proliferation, autophagy, and resistance to 4-hydroxytamoxifen-induced cytotoxicity in estrogen receptor-positive breast cancer cells. J Biol Chem (2010) 0.89
The Role of Interferon Regulatory Factor-1 (IRF1) in Overcoming Antiestrogen Resistance in the Treatment of Breast Cancer. Int J Breast Cancer (2011) 0.88
Induction of Hsp22 (HspB8) by estrogen and the metalloestrogen cadmium in estrogen receptor-positive breast cancer cells. Cell Stress Chaperones (2007) 0.88
Xanthohumol suppresses oestrogen-signalling in breast cancer through the inhibition of BIG3-PHB2 interactions. Sci Rep (2014) 0.87
Targeting BIG3-PHB2 interaction to overcome tamoxifen resistance in breast cancer cells. Nat Commun (2013) 0.86
Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation. Ann Oncol (2013) 0.86
Short wavelength automated perimetry and tamoxifen use. Br J Ophthalmol (2004) 0.84
Combinational treatment of gap junctional activator and tamoxifen in breast cancer cells. Anticancer Drugs (2010) 0.83
Arsenic abrogates the estrogen-signaling pathway in the rat uterus. Reprod Biol Endocrinol (2010) 0.82
The Wilms' tumor suppressor WT1 regulates expression of members of the epidermal growth factor receptor (EGFR) and estrogen receptor in acquired tamoxifen resistance. Anticancer Res (2010) 0.82
The Wilms' tumor suppressor WT1 induces estrogen-independent growth and anti-estrogen insensitivity in ER-positive breast cancer MCF7 cells. Oncol Rep (2010) 0.82
p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells. Oncotarget (2015) 0.82
Modulation of xenobiotic receptors by steroids. Molecules (2013) 0.82
Disruption of the ER-α36-EGFR/HER2 positive regulatory loops restores tamoxifen sensitivity in tamoxifen resistance breast cancer cells. PLoS One (2014) 0.81
MGMT inhibition restores ERα functional sensitivity to antiestrogen therapy. Mol Med (2012) 0.81
Jostling for position: optimizing linker location in the design of estrogen receptor-targeting PROTACs. ChemMedChem (2010) 0.81
Regulation of tamoxifen sensitivity by a PAK1-EBP1 signalling pathway in breast cancer. Br J Cancer (2013) 0.81
SERPINA1 is a direct estrogen receptor target gene and a predictor of survival in breast cancer patients. Oncotarget (2015) 0.81
The changing role of ER in endocrine resistance. Breast (2015) 0.80
A small molecule with anticancer and antimetastatic activities induces rapid mitochondrial-associated necrosis in breast cancer. J Pharmacol Exp Ther (2015) 0.80
Estrogen receptor-α directly regulates the hypoxia-inducible factor 1 pathway associated with antiestrogen response in breast cancer. Proc Natl Acad Sci U S A (2015) 0.79
17Beta-estradiol elevates cGMP and, via plasma membrane recruitment of protein kinase GIalpha, stimulates Ca2+ efflux from rat hepatocytes. J Biol Chem (2010) 0.79
Function of RasGRP3 in the formation and progression of human breast cancer. Mol Cancer (2014) 0.78
Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers. Front Oncol (2015) 0.78
CAPER, a novel regulator of human breast cancer progression. Cell Cycle (2014) 0.77
Estrogen receptor alpha deletion enhances the metastatic phenotype of Ron overexpressing mammary tumors in mice. Mol Cancer (2012) 0.77
Effect of Berry Extracts and Bioactive Compounds on Fulvestrant (ICI 182,780) Sensitive and Resistant Cell Lines. Int J Breast Cancer (2012) 0.77
A new class of small molecule estrogen receptor-alpha antagonists that overcome anti-estrogen resistance. Oncotarget (2015) 0.76
Anti-Tumoral Activity of a Short Decapeptide Fragment of the Alzheimer's Abeta Peptide. Int J Pept Res Ther (2010) 0.76
A study of the relationship of metabolic MR parameters to estrogen dependence in breast cancer xenografts. NMR Biomed (2015) 0.76
CYP2D6 polymorphisms may predict occurrence of adverse effects to tamoxifen: a preliminary retrospective study. Breast Cancer (Dove Med Press) (2017) 0.75
Plumbagin sensitizes breast cancer cells to tamoxifen-induced cell death through GRP78 inhibition and Bik upregulation. Sci Rep (2017) 0.75
Enhancement of the bioavailability of a novel anticancer compound (acetyltanshinone IIA) by encapsulation within mPEG-PLGA nanoparticles: a study of formulation optimization, toxicity, and pharmacokinetics. Oncotarget (2017) 0.75
Estrogen receptor negativity in breast cancer: A cause or consequence? Biosci Rep (2016) 0.75
IGF-1 Receptor Modulates FoxO1-mediated Tamoxifen Response in Breast Cancer Cells. Mol Cancer Res (2017) 0.75
Therapeutic advances in BIG3-PHB2 inhibition targeting the crosstalk between estrogen and growth factors in breast cancer. Cancer Sci (2015) 0.75
Tamoxifen Induces Cytotoxic Autophagy in Glioblastoma. J Neuropathol Exp Neurol (2016) 0.75
Integrative "omic" analysis for tamoxifen sensitivity through cell based models. PLoS One (2014) 0.75
A kinetic model identifies phosphorylated estrogen receptor-α (ERα) as a critical regulator of ERα dynamics in breast cancer. FASEB J (2015) 0.75
Human 3β-hydroxysteroid dehydrogenase type 1 in human breast cancer: clinical significance and prognostic associations. Cancer Med (2016) 0.75
17β-Oestradiol promotes differentiation of human embryonic stem cells into dopamine neurons via cross-talk between insulin-like growth factors-1 and oestrogen receptor β. J Cell Mol Med (2017) 0.75
BRCA1-mimetic compound NSC35446.HCl inhibits IKKB expression by reducing estrogen receptor-α occupancy in the IKKB promoter and inhibits NF-κB activity in antiestrogen-resistant human breast cancer cells. Breast Cancer Res Treat (2017) 0.75
Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6 (CYP2D6) genotype. Clin Pharmacol Ther (2011) 3.09
Multidrug resistance in breast cancer: a meta-analysis of MDR1/gp170 expression and its possible functional significance. J Natl Cancer Inst (1997) 2.88
Clinical Pharmacogenetics Implementation Consortium guideline for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants. Clin Pharmacol Ther (2013) 2.38
MCF7/LCC9: an antiestrogen-resistant MCF-7 variant in which acquired resistance to the steroidal antiestrogen ICI 182,780 confers an early cross-resistance to the nonsteroidal antiestrogen tamoxifen. Cancer Res (1997) 1.74
A SNP in steroid receptor coactivator-1 disrupts a GSK3β phosphorylation site and is associated with altered tamoxifen response in bone. Mol Endocrinol (2011) 1.45
Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients. Pharmacogenomics J (2009) 1.43
Comparative tracking error analysis of five different optical tracking systems. Comput Aided Surg (2000) 1.12
Molecular and pharmacological aspects of antiestrogen resistance. J Steroid Biochem Mol Biol (2001) 1.06
Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res Treat (1993) 0.99
Hormonal carcinogenesis in breast cancer: cellular and molecular studies of malignant progression. Breast Cancer Res Treat (1994) 0.89
Lack of association between oestrogen receptor polymorphisms and change in bone mineral density with tamoxifen therapy. Br J Cancer (2009) 0.88
Autoantibodies to the nuclear phosphoprotein nucleophosmin in breast cancer patients. Cancer Epidemiol Biomarkers Prev (1998) 0.87
Aromatase inhibitor-induced modulation of breast density: clinical and genetic effects. Br J Cancer (2013) 0.87
Genome-wide discovery of genetic variants affecting tamoxifen sensitivity and their clinical and functional validation. Ann Oncol (2013) 0.86
Competitive and allosteric interactions in ligand binding to P-glycoprotein as observed on an immobilized P-glycoprotein liquid chromatographic stationary phase. Mol Pharmacol (2001) 0.85
Maternal and prepubertal diet, mammary development and breast cancer risk. J Nutr (2001) 0.85
Development of an immobilized P-glycoprotein stationary phase for on-line liquid chromatographic determination of drug-binding affinities. J Chromatogr B Biomed Sci Appl (2000) 0.84
Estrogen receptor genotypes, menopausal status, and the effects of tamoxifen on lipid levels: revised and updated results. Clin Pharmacol Ther (2010) 0.83
Secretion of insulin-like growth factor-I (IGF-I) and IGF-binding proteins from bovine mammary tissue in vitro. J Endocrinol (1991) 0.83
The enantioselective binding of mefloquine enantiomers to P-glycoprotein determined using an immobilized P-glycoprotein liquid chromatographic stationary phase. Pharm Res (2001) 0.82
Genetic variation in radiation and platinum pathways predicts severe acute radiation toxicity in patients with esophageal adenocarcinoma treated with cisplatin-based preoperative radiochemotherapy: results from the Eastern Cooperative Oncology Group. Cancer Chemother Pharmacol (2011) 0.81
Acquisition of an antiestrogen-resistant phenotype in breast cancer: role of cellular and molecular mechanisms. Cancer Treat Res (1996) 0.81
Constitutive expression of the steroid sulfatase gene supports the growth of MCF-7 human breast cancer cells in vitro and in vivo. Endocrinology (2001) 0.80
The effects of therapy on estrogen receptors in breast cancer. J Steroid Biochem (1985) 0.79
Different techniques for drug cytotoxicity evaluation on MCF-7 human breast cancer cell line. Anticancer Res (1987) 0.77
Effects of energy balance on hepatic capacity for oleate and propionate metabolism and triglyceride secretion. J Dairy Sci (1991) 0.77
Estrogens, phytoestrogens, and breast cancer. Adv Exp Med Biol (1996) 0.76
Predictive value of some clinical and pathological parameters on upper level axillary lymph node involvement in breast cancer. Anticancer Res (1992) 0.76
Distribution of lipid in hepatic tissue of dairy goats in positive and negative energy balance. Zentralbl Veterinarmed A (1989) 0.75
Use of ERE and reporter gene constructs to assess putative estrogenic activity. J Med Food (1999) 0.75
Insulin-like growth factor (IGF)-I and -II and IGF binding proteins in serum and mammary secretions during the dry period and early lactation in dairy cows. J Anim Sci (1991) 0.75
Effect of 17-beta-estradiol on doxorubicin cytotoxicity in human breast cancer cell culture. Anticancer Res (1989) 0.75